Fri, April 21, 2023
Thu, April 20, 2023
Wed, April 19, 2023

Liisa Bayko Maintained (BCRX) at Buy with Decreased Target to $10 on, Apr 20th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-10-on-apr-20th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Liisa Bayko of Evercore ISI Group, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Buy with Decreased Target from $13 to $10 on, Apr 20th, 2023.

Liisa has made no other calls on BCRX in the last 4 months.



There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 1 agrees with Liisa's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Reiterated at Hold and Held Target at $10 on, Tuesday, March 14th, 2023


These are the ratings of the 2 analyists that currently disagree with Liisa


  • Jonathan Wolleben of "JMP Securities" Reiterated at Buy and Held Target at $16 on, Wednesday, February 22nd, 2023
  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $30 on, Wednesday, February 22nd, 2023

Publication Contributing Sources